Hansa Biopharma has been granted a patent for a novel polypeptide with IgG cysteine protease activity. The polypeptide can be used for the prevention or treatment of diseases mediated by IgG, as well as for the analysis of IgG. The composition includes a variant of the polypeptide sequence that produces more IgG cleavage fragments and is less immunogenic than IdeS. The variant also has specific amino acid substitutions and deletions. GlobalData’s report on Hansa Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hansa Biopharma AB - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hansa Biopharma, peptide pharmacophores was a key innovation area identified from patents. Hansa Biopharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for a polypeptide with igg cysteine protease activity

Source: United States Patent and Trademark Office (USPTO). Credit: Hansa Biopharma AB

A recently granted patent (Publication Number: US11667905B2) discloses a composition comprising a polypeptide with IgG cysteine protease activity. The polypeptide is a variant of a specific sequence (SEQ ID NO:2) and has certain characteristics. Firstly, it is at least 50% identical to SEQ ID NO:2. Secondly, it has a cysteine (C) at a specific position corresponding to position 94 of another sequence (SEQ ID NO:1). Thirdly, it has specific amino acids (lysine, histidine, aspartic acid) at positions corresponding to positions 84, 262, 284, and 286 of SEQ ID NO:1. The polypeptide is designed to produce a greater quantity of IgG cleavage fragments compared to IdeS and/or be less immunogenic than IdeS, another protein with IgG cleavage activity. The variant of SEQ ID NO:2 may also have a positively charged amino acid at positions corresponding to positions 130 and/or 131 of SEQ ID NO:1, and may not include a specific contiguous sequence (NQTN). Additionally, the first twenty residues at the N terminus of SEQ ID NO:2 may be deleted.

The patent also covers other aspects related to the composition. It mentions that the variant of SEQ ID NO:2 can be at least 80% identical to SEQ ID NO:2. The composition can consist of or include sequences from SEQ ID NOs: 3 to 16. The polypeptide in the composition should produce at least 1.5 fold more IgG cleavage fragments than IdeS in the same assay and be less immunogenic, with an immunogenicity no more than 85% of IdeS in the same assay.

The patent further describes methods and uses of the composition. It includes a polynucleotide or expression vector containing a nucleic acid sequence encoding the polypeptide, as well as a method for prevention or treatment of a disease or condition by administering the polypeptide to a subject. The disease or condition can be mediated by pathogenic IgG antibodies. The method can also be used for the cleavage of IgG ex vivo or in blood samples from subjects with IgG-mediated diseases. Other methods involve contacting a sample containing IgG with the polypeptide to allow IgG cleavage, and using the composition to improve the benefit of a therapy or therapeutic agent.

The patent also covers specific methods for the treatment of cancer or other diseases, where the composition is administered to cleave IgG molecules in the plasma of the subject, followed by subsequent administration of an antibody for the treatment of the cancer or disease. The time interval between the two administrations can range from 2 hours to 21 days. The patent lists various cancers and diseases that can be treated using this method.

Overall, the granted patent discloses a composition comprising a polypeptide with IgG cysteine protease activity and provides methods and uses for the composition in the prevention or treatment of diseases mediated by pathogenic IgG antibodies, as well as in the cleavage of IgG molecules.

To know more about GlobalData’s detailed insights on Hansa Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies